Journal
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
Volume 16, Issue 5, Pages E154-E159Publisher
WILEY
DOI: 10.1111/ajco.13365
Keywords
adverse effects; cancer; checkpoint inhibitor; combination immunotherapy; T cell
Categories
Funding
- Beijing Municipal Science and Technology Commission [Z181100001718104]
- Science Foundation of Peking University Cancer Hospital [18-02, 2020-4]
- BeijingMunicipal Administration of Hospitals IncubatingProgram [PX2020045]
Ask authors/readers for more resources
With the development of cancer immunotherapy, the combination strategy is becoming prevalent. Multiple relevant clinical trials are ongoing in this field. However, immune-related adverse events (irAEs) occurred more frequently, showing a different pattern from single-agent therapy. It is necessary for clinicians to learn about the characteristics of AEs from combination immunotherapy, and master the skills to deal with them. In this article, we reviewed presently published data about AEs from combination immunotherapy of cancers. We believe a full-scale view about this new treatment strategy will facilitate oncologists to better understand tumor immune response. With cutting edge knowledge, an experienced team can minimize these AEs and help patients to achieve high-quality long-term survival.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available